Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Combination product
Study Type: Observational
SUMMARY
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age 18 years old or older
• Capable of giving informed consent
• Diagnosis of cancer scheduled for treatment according to treating physician's discretion
• Life expectancy \>1 year
• For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs
Locations
Other Locations
Italy
University of Bologna
NOT_YET_RECRUITING
Bologna
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
NOT_YET_RECRUITING
Palermo
Serbia
University of Belgrade, Clinical Center of Serbia
RECRUITING
Belgrade
University of Belgrade, Clinical Hospital Center Bezanijska kosa
RECRUITING
Belgrade
Contact Information
Primary
Edina Cenko
dimec.epicardio@unibo.it
+3905121444911
Backup
Maria Bergami
dimec.epicardio@unibo.it
+3905121444911
Time Frame
Start Date: 2025-05-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 10000
Treatments
Breast cancer
Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs.~(Non-interventional prospective patient registry)
Female and Male
Diagnosis of cancer scheduled for treatment according to the treating physician's discretion.~(Non-interventional patient registry)
Related Therapeutic Areas
Sponsors
Collaborators: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Leads: University of Bologna